Ask AI
ProCE Banner Activity

Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: Efficacy and Safety Considerations 

PDF

Downloadable resource covering efficacy, dosing considerations, and safety of bispecific antibodies for relapsed/refractory multiple myeloma

Released: January 30, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients  

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Partners

Smart Patients

ProCE Banner

Target Audience

This activity is intended for hematologists/oncologists, oncology nurses and nurse practitioners, physician assistants, pharmacists and other healthcare professionals involved in the care and treatment of patients with RRMM.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret pivotal clinical trial data on BCMA bispecific antibodies, including efficacy, safety, and use in earlier lines of therapy

  • Apply evidence-based strategies to initiate BCMA BsAb therapy and monitor for key adverse events (eg, CRS, ICANS, infections) across diverse practice settings

  • Design multidisciplinary care coordination strategies to support therapy adherence and treatment continuation in patients transitioning from academic to community settings

  • Integrate patient education and shared decision-making tools to align treatment with patient goals and improve persistence

Disclosure

Primary Author

Alfred Garfall, MD: researcher: CRISPR Therapeutics, Johnson & Johnson, Novartis; consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Gracell, GSK, Johnson & Johnson, Novartis, Regeneron, Smart Immune.